HIV dual therapy shows promise February 27, 2017 A dual-drug regiment to treat HIV could soon be a reality, according to results presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Single-tablet HIV drug approved by FDA August 26, 2014 By Tracey Walker FDA has approved abacavir 600 mg, dolutegravir 50 mg (Tivicay) and lamivudine 300 mg (Triumeq, ViiV Healthcare) as as a first-line therapy to treat HIV. FDA approves new once-daily treatment option for HIV Dolutegravir, a new, once-daily option, may allow improved personalization of a patient’s medication regimen. New molecular entity: Tivicay An integrase strand transfer inhibitor for treatment of HIV 1 infection in adults and pediatric patients aged 12 years and older and weighing at least 40 kilograms, as part of combination antiretroviral therapy. New HIV drug approved August 13, 2013 By Tracey Walker FDA this week approved integrase strand transfer inhibitor dolutegravir (Tivicay, ViiV Healthcare , GlaxoSmithKline) to treat HIV-1 infection.